BLTE
Belite Bio, Inc
NASDAQ · USHealthcareBiotechnology
$152.84+1.84%
Price as of Jul 20, 2026
BLTE growth
Belite Bio, Inc growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -88.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +86.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -95.8%
- Free cash flow
- -26.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.